$VTGN News

Vistagen Announces Its Data From PALISADE-3 Phase 3 Trial Of Fasedienol Demonstrates Well-Toleration, No Drug-Related Safety Concerns

Vistagen Completes Last Patient Visit in PALISADE-4 Phase 3 Public Speaking Challenge Study of Fasedienol for Acute Treatment of Social Anxiety Disorder, With Topline Results Expected In Q2

Vistagen Receives "Study May Proceed" Letter From FDA Under IND Application For Refisolone Nasal Spray For Treatment Of Vasomotor Symptoms Due To Menopause

Helus Pharma Stock Tumbles As Anxiety Drug Study Disappoints

Vistagen to Participate in the 46th Annual TD Cowen Healthcare Conference

VistaGen Therapeutics, Inc. Q3 2026 Earnings Call Summary

Vistagen Therapeutics shares are trading lower after the company reported worse-than-expected Q3 financial results.

Vistagen Therapeutics shares are trading lower after the company reported worse-than-expected Q3 financial results.

Vistagen Therapeutics Inc (VTGN) Q3 2026 Earnings Call Highlights: Progress in Clinical Trials ...

Vistagen Therapeutics Inc (NASDAQ:VTGN) Reports Mixed Q3 Results Amid Key Clinical Trial Updates

VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Lags Revenue Estimates

Vistagen Reports Fiscal Year 2026 Third Quarter Financial Results and Provides Corporate Update

Vistagen Therapeutics, Inc. (VTGN) Q3 2026 Earnings Call Transcript

Vistagen Therapeutics shares are trading lower after the company reported worse-than-expected Q3 financial results.

Vistagen Therapeutics Earnings Report: Q3 Overview

VistaGen Therapeutics Q3 EPS $(0.45) Misses $(0.44) Estimate, Sales $303.000K Miss $366.000K Estimate

Vistagen to Report Fiscal Year 2026 Third Quarter Results and Host Corporate Update Conference Call on February 12, 2026

William Blair Downgrades Vistagen Therapeutics to Market Perform

Maxim Group Downgrades Vistagen Therapeutics to Hold

Jefferies Downgrades Vistagen Therapeutics to Hold, Lowers Price Target to $0.9